Adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG) now have a small interfering RNA (siRNA) treatment option administered subcutaneously every 3 months. The US Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals' cemdisiran (Livsayis), making it the first siRNA therapy approved for gMG and the only FDA-approved gMG treatment with quarterly subcutaneous dosing, according to the company's announcement.
Cemdisiran targets messenger RNA encoding complement component 5 (C5), reducing C5 production and inhibiting terminal complement activation implicated in neuromuscular junction damage.
Approval was supported by the phase 3 NIMBLE trial, a randomized, double-blind, placebo-controlled study involving 284 patients, as detailed in the FDA-approved prescribing information. The trial evaluated cemdisiran alone, a C5-inhibiting monoclonal antibody alone, a combination of both agents, or placebo. Background immunosuppressive treatment was permitted.
The primary endpoint was change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline to week 24. In the primary analysis population of 123 patients, cemdisiran produced a least-squares mean improvement of 4.5 points vs 2.2 points with placebo, a placebo-adjusted difference of 2.3 points. An improvement of at least 3 points occurred in 76.6% vs 44.1% of patients, respectively.
For the key secondary endpoint, Quantitative Myasthenia Gravis (QMG) scores improved by 4.2 points with cemdisiran vs 1.5 points with placebo, representing a placebo-adjusted improvement of 2.8 points. At least a 5-point QMG improvement occurred in 48.4% vs 19% of patients. Regeneron reported improvements beginning within 2 weeks and maintained through 24 weeks.
The prescribing information includes a boxed warning for serious meningococcal infections, and cemdisiran is available only through a restricted Risk Evaluation and Mitigation Strategy program. It specifies meningococcal vaccination at least 2 weeks before treatment and antibacterial prophylaxis for patients requiring urgent treatment who are not up to date with vaccination. The recommended dose is 567 mg subcutaneously every 3 months, administered by a health care provider.
Adverse reactions with cemdisiran vs placebo included injection-site reactions (8% vs 3%), viral infections (6% vs 4%), and urinary tract infections (5% vs 4%). The label also warns about other serious infections associated with reduced complement activity. Initiation is contraindicated in patients with an unresolved serious Neisseria meningitidis infection.
Sources: Regeneron, Livsayis prescribing information
